Biocryst Pharmaceuticals Stock Investor Sentiment
| BCRX Stock | USD 7.50 0.01 0.13% |
Slightly above 59% of all BioCryst Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
59
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioCryst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioCryst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
BioCryst Historical Sentiment
Although BioCryst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding BioCryst, such as negative comments on social media and news outlets, may cause fear in the market and push BioCryst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of BioCryst.
BioCryst |
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.
BioCryst Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3 | 09/24/2024 |
2 | BioCryst awarded 69M influenza treatment contract from U.S. HHS | 09/30/2024 |
3 | BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO | 10/14/2024 |
4 | BioCryst earnings matched, revenue topped estimates | 11/04/2024 |
5 | BioCryst Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong ORLADEYO Growth ... | 11/05/2024 |
6 | Earnings call Royalty Pharma reports robust Q3 growth, raises guidance | 11/06/2024 |
7 | Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3 | 11/08/2024 |
8 | BioCrysts SWOT analysis stock outlook amid orladeyo success, pipeline shifts | 11/12/2024 |
9 | BioCryst Launches ORLADEYO in Ireland | 11/18/2024 |
10 | Segall Bryant Hamill LLC Sells 36,105 Shares of BioCryst Pharmaceuticals, Inc. | 11/21/2024 |
11 | Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc. | 11/27/2024 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.